PCSK9 inhibitors

New drug options, risk factors added to US heart guidelines
New drug options, risk factors added to US heart guidelines
Reuters
statins
PCSK9 inhibitors
Flag link:
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Fierce Pharma
Amgen
Sanofi
Regeneron
PCSK9 inhibitors
Supreme Court
Praluent
Repatha
Flag link:
Are These Disappointing Drugs Back on Track to Billions?
Are These Disappointing Drugs Back on Track to Billions?
Motley Fool
PCSK9 inhibitors
Sanofi
Regeneron
Amgen
Praluent
Repatha
Flag link:
PCSK9s appear to be meeting less payer resistance
PCSK9s appear to be meeting less payer resistance
Biopharma Dive
PCSK9 inhibitors
payers
Flag link:
The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs
The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs
Forbes
cholesterol
PCSK9 inhibitors
Sanofi
Regeneron
Praluent
Amgen
Repatha
Flag link:
NovoNordisk’s CSO openly addresses state of pharma sector
NovoNordisk’s CSO openly addresses state of pharma sector
GoinPharma
Novo Nordisk
Victoza
NASH
PCSK9 inhibitors
Flag link:
The Medicines Co., in pivot to pipeline PCSK9 med, secures $270M asset sale
The Medicines Co., in pivot to pipeline PCSK9 med, secures $270M asset sale
Fierce Pharma
The Medicines Company
PCSK9 inhibitors
inclisiran
Vabomere
Flag link:
The Medicines Company PCSK9 Inhibitor Strategy: More Heart Patients Via Lower Pricing
The Medicines Company PCSK9 Inhibitor Strategy: More Heart Patients Via Lower Pricing
Forbes
The Medicines Company
PCSK9 inhibitors
drug pricing
inclisiran
Flag link:
The Medicine Company's Dangerous Bet On Its LDL Cholesterol Lowering Drug
The Medicine Company's Dangerous Bet On Its LDL Cholesterol Lowering Drug
Forbes
The Medicine Company
LDL cholesterol
inclisiran
Alnylam
PCSK9 inhibitors
Flag link:
PCSK9 court saga drags on for Sanofi, Regeneron and Amgen
PCSK9 court saga drags on for Sanofi, Regeneron and Amgen
Biopharma Dive
Sanofi
Regeneron
Amgen
PCSK9 inhibitors
Praluent
Repatha
Flag link:
Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients
Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients
Fierce Pharma
Sanofi
Amgen
PCSK9 inhibitors
diabetes
Regeneron
Praluent
Repatha
Flag link:
Insurers, doctors battle over new heart disease drugs
Insurers, doctors battle over new heart disease drugs
CNBC
insurers
cardiovascular disease
statins
PCSK9 inhibitors
Amgen
Regeneron
Sanofi
Repatha
Praluent
Flag link:
In cost debate, Amgen stands by Repatha's value
In cost debate, Amgen stands by Repatha's value
BioPharma Dive
Amgen
Repatha
drug pricing
PCSK9 inhibitors
Praluent
Sanofi
Regeneron
Flag link:
ADA preview: 5 things to watch in diabetes
ADA preview: 5 things to watch in diabetes
BioPharma Dive
ADA
diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Lantus
Tresiba
JNJ
Novo Nordisk
PCSK9 inhibitors
Amgen Regeneron
Sanofi
Apple
Google
insulin
Flag link:
Lilly, Pfizer, et al. back Sanofi and Regeneron in PCSK9 patent appeal. AbbVie doesn't
Lilly, Pfizer, et al. back Sanofi and Regeneron in PCSK9 patent appeal. AbbVie doesn't
Fierce Pharma
Eli Lilly
Pfizer
Sanofi
AbbVie
Regeneron
patents
PCSK9 inhibitors
Repatha
Flag link:
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor
Xtalks
Amgen
patients
PCSK9 inhibitors
Repatha
Flag link:
When it comes to PCSK9s, payers resisted — and sales flopped
When it comes to PCSK9s, payers resisted — and sales flopped
Medical Marketing and Media
PCSK9 inhibitors
payers
Amgen
Sanofi
Regeneron
Repatha
Praluent
Flag link:
Sanofi, Regeneron one step closer to owing PCSK9 royalties as judge upholds Amgen patent ruling
Sanofi, Regeneron one step closer to owing PCSK9 royalties as judge upholds Amgen patent ruling
Fierce Pharma
Sanofi
Regeneron
PCSK9 inhibitors
Amgen
Praluent
Repatha
Flag link:
No early success for Regeneron, Sanofi in PhIII outcomes study for PCSK9 drug Praluent
No early success for Regeneron, Sanofi in PhIII outcomes study for PCSK9 drug Praluent
Endpoints
Regeneron
Sanofi
Praluent
PCSK9 inhibitors
Flag link:
Data in hand, The Medicines Co. speeds PCSK9 plans
Data in hand, The Medicines Co. speeds PCSK9 plans
BioPharma Dive
The Medicines Company
PCSK9 inhibitors
inclisiran
Flag link:

Pages